ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2017
Novel biomarkers for prediabetes, diabetes, and associated complications.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.Movement disorders : official journal of the Movement Disorder Society · 2021Pooled it
- Potential Markers of Dietary Glycemic Exposures for Sustained Dietary Interventions in Populations without Diabetes.Advances in nutrition (Bethesda, Md.) · 2020Pooled it
- Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial.Journal of medicinal food · 2022Trial
- Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease.Cardiovascular diabetology · 2022Trial
- Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study.Phytotherapy research : PTR · 2019Trial
- Biochemical and Molecular Markers Among Prediabetic and Type 2 Diabetes Mellitus Patients.International journal of endocrinology and metabolism · 2026Article
- Uric Acid-to-HDL Cholesterol Ratio Is Associated with Prediabetes and an Adverse Metabolic Profile: Results from the Genetics of Atherosclerotic Disease (GEA) Study.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Dried blood spot sample extraction for metabolomics and proteomics profiling for clinical trials: a descriptive exploratory study.Scientific reports · 2026Article
- Selected Emerging Biomarkers in Type 2 Diabetes Mellitus: Clinical Insights and Implications for Precision Care.Medicina (Kaunas, Lithuania) · 2026Review
- Identifying Patients with Rapid Progression to Diabetic Retinopathy in Type 2 Diabetes: A Simple Prediction Model for Community Settings.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Hierarchical random forest model, inflammation and oxidative stress as predictors of the atherogenic index of plasma and diabetes progression.Scientific reports · 2025Article
- Association between red cell distribution width and its ratio with albumin and diabetic nephropathy/retinopathy: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Emerging Biomarkers and Nanobiosensing Strategies in Diabetes.Biosensors · 2025Review
- Serum Granulin Concentrations Are Elevated in Prediabetes and Newly Diagnosed Diabetes: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Primary open-angle glaucoma: a perspective from plasma metabolomics.Expert review of molecular diagnostics · 2025Review
- Investigating aging trajectories and determinants in Northern Italy through the Novara cohort study.Scientific reports · 2025Article
- Article
- An immunosensor for the detection ofRSC advances · 2025Article
- Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The number of individuals with prediabetes is expected to grow substantially and estimated to globally affect 482 million people by 2040. Therefore, effective methods for diagnosing prediabetes will be required to reduce the risk of progressing to diabetes and its complications. The current biomarkers, glycated hemoglobin (HbA1c), fructosamine, and glycated albumin have limitations including moderate sensitivity and specificity and are inaccurate in certain clinical conditions. Therefore, identification of additional biomarkers is being explored recognizing that any single biomarker will also likely have inherent limitations. Therefore, combining several biomarkers may more precisely identify those at high risk for developing prediabetes and subsequent progression to diabetes. This review describes recently identified biomarkers and their potential utility for addressing the burgeoning epidemic of dysglycemic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.